Related Experiment Video
Updated: Feb 11, 2026

Production of Disulfide-stabilized Transmembrane Peptide Complexes for Structural Studies
Published on: March 6, 2013
Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2
Piotr F J Lipiński1, Piotr Garnuszek2, Michał Maurin2
1Neuropeptides Department, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawińskiego 5 Str., 02-106, Warszawa, Poland. plipinski@imdik.pan.pl.
Background:
The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several peptide conjugates suitable for the TRNT of MTC have been synthesized, including a very promising minigastrin analogue DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (CP04). In this contribution, we wanted to see whether CP04 binding affinity for CCK-2R is sensitive to the type of the complexed radiometal, as well as to get insights into the structure of CP04-CCK2R complex by molecular modeling.
Results:
In vitro studies demonstrated that there is no significant difference in CCK-2R binding affinity and specific cellular uptake between the CP04 conjugates complexed with [68Ga]Ga3+ or [177Lu]Lu3+. In order to investigate the background of this observation, we proposed a binding model of CP04 with CCK-2R based on homology modeling and molecular docking. In this model, the C-terminal part of the molecule enters the cavity formed between the receptor helices, while the N-terminus (including DOTA and the metal) is located at the binding site outlet, exposed in large extent to the solvent. The radiometals do not influence the conformation of the molecule except for the direct neighborhood of the chelating moiety.
Conclusions:
The model seems to be in agreement with much of structure-activity relationship (SAR) studies reported for cholecystokinin and for CCK-2R-targeting radiopharmaceuticals. It also explains relative insensitivity of CCK-2R affinity for the change of the metal. The proposed model partially fits the reported site-directed mutagenesis data.
Insights
The minigastrin analogue CP04 shows similar binding affinity for the cholecystokinin receptor subtype 2 (CCK-2R) regardless of the radiometal used, supporting its use in theranostic applications for cancers like medullary thyroid carcinoma.
Area of Science:
- Radiopharmaceutical chemistry
- Molecular imaging
- Cancer theranostics
Background:
- The cholecystokinin receptor subtype 2 (CCK-2R) is overexpressed in certain cancers, notably medullary thyroid carcinoma (MTC), making it a key target for diagnostic imaging and targeted radionuclide therapy (TRNT).
- Minigastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) is a promising radiopharmaceutical candidate for MTC theranostics.
Purpose of the Study:
- To evaluate the influence of different radiometals on the binding affinity of CP04 to CCK-2R.
- To elucidate the binding mode of CP04 to CCK-2R through molecular modeling.
Main Methods:
- In vitro binding affinity and cellular uptake studies using CP04 complexed with Gallium-68 ([68Ga]Ga3+) and Lutetium-177 ([177Lu]Lu3+).
- Homology modeling and molecular docking to predict the binding structure of CP04 with CCK-2R.
Main Results:
- CP04 exhibited comparable CCK-2R binding affinity and cellular uptake when complexed with either [68Ga]Ga3+ or [177Lu]Lu3+.
- Molecular modeling revealed that the C-terminal of CP04 binds within the CCK-2R cavity, while the N-terminus with the radiometal remains exposed at the solvent-accessible outlet.
- Radiometal complexation minimally affects the overall conformation of CP04, except in the immediate vicinity of the DOTA chelator.
Conclusions:
- The binding affinity of CP04 to CCK-2R is relatively insensitive to the choice of radiometal, consistent with structure-activity relationship studies.
- The proposed binding model supports the theranostic potential of CP04 for CCK-2R-expressing tumors.
- The model aligns with existing structure-activity relationship data and partially explains site-directed mutagenesis findings.
Related Concept Videos
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Assembly of Complex Microtubule Structures
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Olfactory Receptors: Location and Structure
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Internal Receptors

